Lomitapide (Lojuxta®)

Assessment Status Rapid Review Complete
Drug Lomitapide
Brand Lojuxta®
Indication As an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).
Assessment Process
Rapid review commissioned 09/09/2014
Rapid review completed 15/09/2014
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.